SLC16A1 and neoplasm: However, the combination of both compounds resulted in 29–100% tumour cell killing in six out of seven MCT1+/MCT4− DLBCL lines, confirming that the simultaneous targeting of two key metabolic pathways can deliver a highly pronounced therapeutic effect.